MedStar Authors catalog › Details for: Rheumatoid arthritis in the Women's Health Initiative: methods and baseline evaluation.
Normal view MARC view ISBD view

Rheumatoid arthritis in the Women's Health Initiative: methods and baseline evaluation.

by Walitt, Brian.
Citation: American Journal of Epidemiology. 179(7):917-26, 2014 Apr 1..Journal: American journal of epidemiology.ISSN: 0002-9262.Full author list: Kuller LH; Mackey RH; Walitt BT; Deane KD; Holers VM; Robinson WH; Sokolove J; Chang Y; Moreland LW.UI/PMID: 24569640.Subject(s): Aged | Antibodies, Antinuclear/bl [Blood] | *Antirheumatic Agents/ad [Administration & Dosage] | *Arthritis, Rheumatoid/bl [Blood] | Arthritis, Rheumatoid/ep [Epidemiology] | Arthritis, Rheumatoid/ge [Genetics] | Biological Markers/bl [Blood] | Cytokines/bl [Blood] | Female | Genetic Predisposition to Disease | HLA-DRB1 Chains/bl [Blood] | Humans | Immunologic Factors/bl [Blood] | Middle Aged | *Peptides, Cyclic/bl [Blood] | Peptides, Cyclic/im [Immunology] | Polymerase Chain Reaction | *Rheumatoid Factor/bl [Blood] | Seroepidemiologic Studies | United States/ep [Epidemiology] | *Women's Health/sn [Statistics & Numerical Data]Institution(s): MedStar Washington Hospital CenterDepartment(s): Medicine/RheumatologyActivity type: Journal Article.Medline article type(s): Journal Article | Research Support, N.I.H., ExtramuralOnline resources: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1093/aje/kwu003 (Click here) Abbreviated citation: Am J Epidemiol. 179(7):917-26, 2014 Apr 1.Local Holdings: Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006.Abstract: Second-generation assays for anti-cyclic citrullinated peptide (anti-CCP), a highly sensitive and specific marker for rheumatoid arthritis (RA), have redefined the epidemiology of RA. In the Women's Health Initiative (WHI) RA study (2009-2011), we evaluated the prevalence of anti-CCP positivity among 15,691 (10.2% of 161,808) WHI participants aged 50-79 years who reported RA. Using stored baseline specimens, we measured serum anti-CCP, rheumatoid factor (RF), and antinuclear antibody in a defined sample of 9,988 of black, white, and Hispanic women. In a subset of women, we measured plasma cytokine levels and number of copies of the human leukocyte antigen (HLA)-DRB1 (HLA-DRB1) shared epitope in DNA by means of Luminex polymerase chain reaction typing (Luminex Corporation, Austin, Texas). We validated classification of probable clinical RA in 2 clinics as anti-CCP positivity or self-reported validated use of disease-modifying antirheumatic drugs (DMARDs). The prevalence of anti-CCP positivity was 8.1%, and the prevalence of RF positivity was approximately 16.0%. DMARD use including prednisone was reported by 1,140 (11.4%) participants (841 excluding prednisone) but by 57.5% of anti-CCP-positive women. The prevalence of 2 shared epitopes was also much higher for anti-CCP-positive women (18.2%, as opposed to only 5.5% for women with anti-CCP-negative DMARD-positive RA and 6.6% for anti-CCP-negative, RF-negative DMARD nonusers). Median cytokine levels were much higher for anti-CCP-positive/RF-positive women. Women with anti-CCP-positive RA and anti-CCP-negative RA had different characteristics with regard to HLA shared epitope, cigarette smoking, and inflammation (cytokines).

Powered by Koha